OIP5 is a highly expressed potential therapeutic target for colorectal and gastric cancers

BMB Reports

Volumn 43, Issue 5, 2010, Pages 349-354

  Chun, Ho Kyung ^b   Chung, Kyung Sook ^a   Kim, Hee Cheol ^b   Kang, Jung Eun ^a,d   Kang, Min Ah ^a,d   Kim, Jong Tae ^a   Choi, Eun Hwa ^a   Jung, Kyeong Eun ^c   Kim, Moon Hee ^c   Song, Eun Young ^a   Kim, Seon Young ^a   Won, Misun ^a   Lee, Hee Gu ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Samchully Pharm Co Ltd   (South Korea)

^d University of Science and Technology (UST)   (South Korea)

Author keywords

Colorectal cancer; Gastric cancer; LINT 25; OIP5; Therapeutic target

Indexed keywords

NEISSERIA GONORRHOEAE;

EID: 77953533833     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2010.43.5.349     Document Type: Article

References (23)

1. Williams, J. M., Chen, G. C., Zhu, L. and Rest, R. F. (1998) Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth. Mol. Microbiol. 27, 171-186.
2. Pawlak, A., Toussaint, C., Levy, I., Bulle, F., Poyard, M., Barouki, R. and Guellaen, G. (1995) Characterization of a large population of mRNAs from human testis. Genomics 26, 151-158.
3. Naetar, N., Hutter, S., Dorner, D., Dechat, T., Korbei, B., Gotzmann, J., Beug, H. and Foisner, R. (2007) LAP2alpha-binding protein LINT-25 is a novel chromatin-associated protein involved in cell cycle exit. J. Cell Sci. 120, 737-747.
4. Fujita, Y., Hayashi, T., Kiyomitsu, T., Toyoda, Y., Kokubu, A., Obuse, C. and Yanagida, M. (2007) Priming of centromere for CENP-A recruitment by human hMis18alpha, hMis18beta, and M18BP1. Dev. Cell 12, 17-30.
5. Chung, K. S., Jang, Y. J., Kim, N. S., Park, S. Y., Choi, S. J., Kim, J. Y., Ahn, J. H., Lee, H. J., Lim, J. H., Song, J. H., Ji, J. H., Oh, J. H., Song, K. B., Yoo, H. S. and Won, M. (2007) Rapid screen of human genes for relevance to cancer using fission yeast. J. Biomol. Screen. 12, 568-577.
6. Nakamura, Y., Tanaka, F., Nagahara, H., Ieta, K., Haraguchi, N., Mimori, K., Sasaki, A., Inoue, H., Yanaga, K. and Mori, M. (2007) Opa interacting protein 5 (OIP5) is a novel cancer-testis specific gene in gastric cancer. Ann. Surg. Oncol. 14, 885-892.
7. Woessmann, W., Damm-Welk, C., Fuchs, U. and Borkhardt, A. (2003) RNA interference: new mechanisms for targeted treatment? Rev. Clin. Exp. Hematol. 7, 270-291.
8. Devi, G. R. (2006) siRNA-based approaches in cancer therapy. Cancer. Gene. Ther. 13, 819-829.
9. Kurreck, J. (2004) Expediting target identification and validation through RNAi. Expert. Opin. Biol. Ther. 4, 427-429.
10. Masiero, M., Nardo, G., Indraccolo, S. and Favaro, E. (2007) RNA interference: implications for cancer treatment. Mol. Aspects Med. 28, 143-166.
11. Zhai, D., Jin, C., Huang, Z., Satterthwait, A. C. and Reed, J. C. (2008) Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J. Biol. Chem. 283, 9580-9586.
12. Ruiz-Vela, A., Opferman, J. T., Cheng, E. H. and Korsmeyer, S. J. (2005) Proapoptotic BAX and BAK control multiple initiator caspases. EMBO Rep. 6, 379-385.
13. Mizuta, T., Shimizu, S., Matsuoka, Y., Nakagawa, T., and Tsujimoto, Y. (2007) A Bax/Bak-independent mechanism of cytochrome c release. J. Biol. Chem. 282, 16623-16630.
14. Zong, W. X., Li, C., Hatzivassiliou, G., Lindsten, T., Yu, Q. C., Yuan, J. and Thompson, C. B. (2003) Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J. Cell Biol. 162, 59-69.
15. Andrade, F., Casciola-Rosen, L. A. and Rosen, A. (2004) Granzyme B-induced cell death. Acta Haematol. 111, 28-41.
16. Germain, M., Milburn, J. and Duronio, V. (2008) MCL-1 inhibits BAX in the absence of MCL-1/BAX Interaction. J. Biol. Chem. 283, 6384-6392.
17. Spankuch, B., Kurunci-Csacsko, E., Kaufmann, M. and Strebhardt, K. (2007) Rational combinations of siRNAs targeting Plk1 with breast cancer drugs. Oncogene 26, 5793-5807.
18. Yoo, J. Y., Kim, J. H., Kim, J., Huang, J. H., Zhang, S. N., Kang, Y. A., Kim, H. and Yun, C. O. (2008) Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther. 15, 635-651.
19. Halder, J., Kamat, A. A., Landen, C. N., Jr., Han, L. Y., Lutgendorf, S. K., Lin, Y. G., Merritt, W. M., Jennings, N. B., Chavez-Reyes, A., Coleman, R. L., Gershenson, D. M., Schmandt, R., Cole, S. W., Lopez-Berestein, G. and Sood, A. K. (2006) Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12, 4916-4924.
20. Halder, J., Lin, Y. G., Merritt, W. M., Spannuth, W. A., Nick, A. M., Honda, T., Kamat, A. A., Han, L. Y., Kim, T. J., Lu, C., Tari, A. M., Bornmann, W., Fernandez, A., Lopez-Berestein, G. and Sood, A. K. (2007) Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 67, 10976-10983.
21. Mook, O. R., Baas, F., de Wissel, M. B. and Fluiter, K. (2007) Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol. Cancer Ther. 6, 833-843.
22. Aigner, A. (2006) Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J. Biotechnol. 124, 12-25.
23. Kim, S. I., Shin, D., Choi, T. H., Lee, J. C., Cheon, G. J., Kim, K. Y., Park, M. and Kim, M. (2007) Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol. Ther. 15, 1145-1152.